Expertise in
18
conditions

Maria T. Terreri

M.T. Terreri, 
Sao Paulo, SP, BR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
18
conditions
M.T. Terreri, 
Sao Paulo, SP, BR 

Overview

Maria Terreri practices practicing medicine in Sao Paulo, Brazil.

Ms. Terreri is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Scleroderma, Juvenile Idiopathic Arthritis (JIA), Systemic Sclerosis (SSc), and Takayasu Arteritis.

She is actively involved in clinical research, co-authoring 115 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

M.T. Terreri, Sao Paulo, SP, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

115 Total Publications

Bone microarchitecture impairment in juvenile systemic lupus erythematosus patients: A comparative study.
Bone microarchitecture impairment in juvenile systemic lupus erythematosus patients: A comparative study.
Journal: Lupus
Published: March 18, 2026

Frequently Asked Questions about Maria T. Terreri

Is Maria T. Terreri a top-rated expert for Scleroderma?

MediFind is an objective health platform that identifies experts based on real-world data. Maria T. Terreri is classified as an Distinguished expert for Scleroderma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Maria T. Terreri participate in research or clinical trials?

Yes. Maria T. Terreri has published 115 articles and abstracts on conditions like Scleroderma. You can view a list of Maria T. Terreri's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Terreri's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile